DOI:
10.1055/s-00050348
Indian Journal of Medical and Paediatric Oncology
LinksClose Window
References
Grignani G, Palmerini E, Ferraresi V, D’Ambrosio L, Bertulli R, Asaftei SD. et al.
Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: A non-randomised phase 2 clinical trial.
Lancet Oncol 2015;
16: 98-107
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.